UnitedHealth Group (NYSE: UNH) is facing renewed investor scrutiny as Medicare Advantage reimbursement concerns add another layer of uncertainty to the company’s earnings outlook. The issue gained attention after Mairs & Power Balanced Fund discussed UnitedHealth in its first-quarter 2026 investor letter, pointing to slower expected payment growth as a potential challenge for the healthcare giant.
The concern centers on Medicare Advantage, a key business area for large managed-care companies. These plans depend heavily on government reimbursement rates, and when payment increases slow while medical costs remain elevated, insurers may be forced to adjust benefits, pricing, or market strategy. For UnitedHealth, that creates a difficult balance between protecting margins and keeping its plans attractive to members.
Mairs & Power noted that UnitedHealth has faced several missteps over the past year and came under fresh pressure after the Centers for Medicare & Medicaid Services released a nearly flat proposed increase for 2027 Medicare Advantage payments. That compares with the roughly 5% level for 2026, making the change more meaningful for investors already focused on healthcare cost trends.
According to the official CMS 2027 Medicare Advantage and Part D Advance Notice, average Medicare Advantage payments were projected to rise only 0.09% year over year, representing more than $700 million in additional payments if finalized.
The risk for UnitedHealth is not only lower reimbursement growth. Mairs & Power said management indicated that benefit reductions may be needed to offset the pressure. While that could help defend profitability, it may also reduce plan appeal and lead some members to consider competing Medicare Advantage options.
That concern comes as investors are already watching UnitedHealth’s medical cost trends closely. The company has remained a revenue powerhouse, but rising healthcare utilization has pressured sentiment. Earlier concerns around profitability became clear when UnitedHealth reported $113.2 billion in revenue while facing higher medical costs, showing why reimbursement rates now carry greater importance for future earnings.
Despite the latest concerns, UNH stock has shown resilience. Shares gained about 3.3% over the past month and closed near $379.86 on June 1, 2026. The company’s market value stood around $345 billion, while the stock traded between $234.60 and $404.15 over the past 52 weeks.
Institutional positioning also shows a more cautious tone. Hedge fund ownership fell to 130 funds at the end of the first quarter, down from 145 in the previous quarter. Even so, UnitedHealth remained one of the most widely held healthcare names among hedge funds, reflecting its scale and long-term importance in the sector.
Read More
There are still reasons investors have not abandoned the stock. Bernstein recently raised its price target on UnitedHealth, supported by expectations for an earnings recovery. The company’s broad business model, including Optum’s healthcare services, pharmacy, and data operations, gives it more flexibility than smaller insurers that rely more narrowly on health plan margins.
For now, UnitedHealth’s challenge is execution. Investors want to see whether the company can manage Medicare Advantage plan changes without losing meaningful membership or allowing medical costs to erode margins further. Until that becomes clearer, reimbursement concerns are likely to remain a major factor shaping UNH stock sentiment.
Make Swikblog your go-to source on Google for reliable updates, smart insights, and daily trends.
